<?xml version='1.0' encoding='utf-8'?>
<document id="22927483"><sentence text="Ontogeny and sorafenib metabolism."><entity charOffset="13-22" id="DDI-PubMed.22927483.s1.e0" text="sorafenib" /></sentence><sentence text="To investigate the role of ontogeny in sorafenib metabolism to the equipotent active metabolite sorafenib N-oxide"><entity charOffset="39-48" id="DDI-PubMed.22927483.s2.e0" text="sorafenib" /><entity charOffset="96-113" id="DDI-PubMed.22927483.s2.e1" text="sorafenib N-oxide" /><pair ddi="false" e1="DDI-PubMed.22927483.s2.e0" e2="DDI-PubMed.22927483.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22927483.s2.e0" e2="DDI-PubMed.22927483.s2.e1" /></sentence><sentence text="" /><sentence text="Steady-state pharmacokinetic studies of sorafenib and metabolites were conducted in 30 children and young adults (17 males; median age, 9"><entity charOffset="40-49" id="DDI-PubMed.22927483.s4.e0" text="sorafenib" /></sentence><sentence text="5 years) receiving sorafenib 150 mg/m(2) or 200 mg/m(2) twice daily"><entity charOffset="19-28" id="DDI-PubMed.22927483.s5.e0" text="sorafenib" /></sentence><sentence text=" Sorafenib metabolism was evaluated in vitro at 10 μmol/L using a panel of purified human cytochrome P450 (CYP) enzymes"><entity charOffset="1-10" id="DDI-PubMed.22927483.s6.e0" text="Sorafenib" /></sentence><sentence text=" Sorafenib metabolism and CYP3A4 expression was evaluated in 52 human liver samples from donors of ≤20 years old"><entity charOffset="1-10" id="DDI-PubMed.22927483.s7.e0" text="Sorafenib" /></sentence><sentence text=" The drug-drug interaction potential between sorafenib and azole antifungal agents was evaluated in vitro and in vivo"><entity charOffset="45-54" id="DDI-PubMed.22927483.s8.e0" text="sorafenib" /><entity charOffset="59-64" id="DDI-PubMed.22927483.s8.e1" text="azole" /><pair ddi="false" e1="DDI-PubMed.22927483.s8.e0" e2="DDI-PubMed.22927483.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22927483.s8.e0" e2="DDI-PubMed.22927483.s8.e1" /></sentence><sentence text="" /><sentence text="No age-related differences in sorafenib apparent oral clearance were observed"><entity charOffset="30-39" id="DDI-PubMed.22927483.s10.e0" text="sorafenib" /></sentence><sentence text=" Mean sorafenib N-oxide metabolite ratio was 0"><entity charOffset="6-23" id="DDI-PubMed.22927483.s11.e0" text="sorafenib N-oxide" /></sentence><sentence text="27 ± 0" /><sentence text="14" /><sentence text=" In children of ≤10 years of age, boys had approximately 2-fold higher N-oxide ratios than girls (0"><entity charOffset="71-78" id="DDI-PubMed.22927483.s14.e0" text="N-oxide" /></sentence><sentence text="40 ± 0" /><sentence text="15 vs" /><sentence text=" 0" /><sentence text="22 ± 0" /><sentence text="12, P = 0" /><sentence text="026)" /><sentence text=" Of the CYPs evaluated, sorafenib was exclusively metabolized to sorafenib N-oxide by CYP3A4"><entity charOffset="24-33" id="DDI-PubMed.22927483.s21.e0" text="sorafenib" /><entity charOffset="65-82" id="DDI-PubMed.22927483.s21.e1" text="sorafenib N-oxide" /><pair ddi="false" e1="DDI-PubMed.22927483.s21.e0" e2="DDI-PubMed.22927483.s21.e0" /><pair ddi="false" e1="DDI-PubMed.22927483.s21.e0" e2="DDI-PubMed.22927483.s21.e1" /></sentence><sentence text=" A trend for increased N-oxide formation in boys was observed in liver samples, which correlated with CYP3A4 mRNA expression"><entity charOffset="23-30" id="DDI-PubMed.22927483.s22.e0" text="N-oxide" /></sentence><sentence text=" Posaconazole and voriconazole potently inhibited sorafenib N-oxide formation in vitro, and reduced sorafenib N-oxide formation in 3 children given sorafenib concurrent with azoles"><entity charOffset="1-13" id="DDI-PubMed.22927483.s23.e0" text="Posaconazole" /><entity charOffset="18-30" id="DDI-PubMed.22927483.s23.e1" text="voriconazole" /><entity charOffset="50-67" id="DDI-PubMed.22927483.s23.e2" text="sorafenib N-oxide" /><entity charOffset="100-117" id="DDI-PubMed.22927483.s23.e3" text="sorafenib N-oxide" /><entity charOffset="148-157" id="DDI-PubMed.22927483.s23.e4" text="sorafenib" /><entity charOffset="174-180" id="DDI-PubMed.22927483.s23.e5" text="azoles" /><entity charOffset="8-13" id="DDI-PubMed.22927483.s23.e6" text="azole" /><entity charOffset="25-30" id="DDI-PubMed.22927483.s23.e7" text="azole" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e0" e2="DDI-PubMed.22927483.s23.e0" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e0" e2="DDI-PubMed.22927483.s23.e6" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e0" e2="DDI-PubMed.22927483.s23.e1" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e0" e2="DDI-PubMed.22927483.s23.e7" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e0" e2="DDI-PubMed.22927483.s23.e2" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e0" e2="DDI-PubMed.22927483.s23.e3" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e0" e2="DDI-PubMed.22927483.s23.e4" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e0" e2="DDI-PubMed.22927483.s23.e5" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e6" e2="DDI-PubMed.22927483.s23.e6" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e6" e2="DDI-PubMed.22927483.s23.e1" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e6" e2="DDI-PubMed.22927483.s23.e7" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e6" e2="DDI-PubMed.22927483.s23.e2" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e6" e2="DDI-PubMed.22927483.s23.e3" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e6" e2="DDI-PubMed.22927483.s23.e4" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e6" e2="DDI-PubMed.22927483.s23.e5" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e1" e2="DDI-PubMed.22927483.s23.e1" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e1" e2="DDI-PubMed.22927483.s23.e7" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e1" e2="DDI-PubMed.22927483.s23.e2" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e1" e2="DDI-PubMed.22927483.s23.e3" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e1" e2="DDI-PubMed.22927483.s23.e4" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e1" e2="DDI-PubMed.22927483.s23.e5" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e7" e2="DDI-PubMed.22927483.s23.e7" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e7" e2="DDI-PubMed.22927483.s23.e2" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e7" e2="DDI-PubMed.22927483.s23.e3" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e7" e2="DDI-PubMed.22927483.s23.e4" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e7" e2="DDI-PubMed.22927483.s23.e5" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e2" e2="DDI-PubMed.22927483.s23.e2" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e2" e2="DDI-PubMed.22927483.s23.e3" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e2" e2="DDI-PubMed.22927483.s23.e4" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e2" e2="DDI-PubMed.22927483.s23.e5" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e3" e2="DDI-PubMed.22927483.s23.e3" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e3" e2="DDI-PubMed.22927483.s23.e4" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e3" e2="DDI-PubMed.22927483.s23.e5" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e4" e2="DDI-PubMed.22927483.s23.e4" /><pair ddi="false" e1="DDI-PubMed.22927483.s23.e4" e2="DDI-PubMed.22927483.s23.e5" /></sentence><sentence text="" /><sentence text="We have identified several factors affecting interpatient variability in sorafenib metabolism to the active N-oxide metabolite including age, sex, and concurrent treatment with azole antifungals"><entity charOffset="73-82" id="DDI-PubMed.22927483.s25.e0" text="sorafenib" /><entity charOffset="108-115" id="DDI-PubMed.22927483.s25.e1" text="N-oxide" /><entity charOffset="177-182" id="DDI-PubMed.22927483.s25.e2" text="azole" /><pair ddi="false" e1="DDI-PubMed.22927483.s25.e0" e2="DDI-PubMed.22927483.s25.e0" /><pair ddi="false" e1="DDI-PubMed.22927483.s25.e0" e2="DDI-PubMed.22927483.s25.e1" /><pair ddi="false" e1="DDI-PubMed.22927483.s25.e0" e2="DDI-PubMed.22927483.s25.e2" /><pair ddi="false" e1="DDI-PubMed.22927483.s25.e1" e2="DDI-PubMed.22927483.s25.e1" /><pair ddi="false" e1="DDI-PubMed.22927483.s25.e1" e2="DDI-PubMed.22927483.s25.e2" /></sentence><sentence text=" This knowledge may provide important considerations for the clinical use of sorafenib in children and possibly other kinase inhibitors undergoing CYP3A4-mediated metabolism"><entity charOffset="77-86" id="DDI-PubMed.22927483.s26.e0" text="sorafenib" /></sentence><sentence text="" /></document>